Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
(WorldNews Switzerland)

Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality Sandoz seeks approval in the same indication as the reference medicine, for prevention of febrile neutropenia, one of the most serious side effects of cancer chemotherapy[1] Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with sevenapproved biosimilars Holzkirchen, September 21, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...